Study Finds Comparable Response to Adjuvant Chemotherapy/Atezolizumab Following Both Pneumonectomy/Bilobectomy and Lobectomy/Sleeve Lobectomy

Boston, MA (May 17, 2022) – IMpower010 was a randomized, multicenter, open-label, phase 3 study done at 227 sites in 22 countries and regions. Eligible patients were 18 years or older with completely resected stage IB (tumors ≥4 cm) to IIIA non-small cell lung cancer (NSCLC). The study established adjuvant atezolizumab as standard of care after chemotherapy in the resected stage II–IIIA population. 

The safety/tolerability of checkpoint inhibitors in pneumonectomy or bilobectomy patients, however, was unclear. All of the patients in the study (n=1,280) received cisplatin-based chemotherapy followed by 1:1 randomization to receive adjuvant treatment with atezolizumab or to best supported care. The study investigated adverse events (AEs), time to adjuvant treatment, and atezolizumab treatment withdrawal and duration by surgery type, pneumonectomy/bilobectomy (P-BL) and lobectomy/sleeve lobectomy (L).

In the atezolizumab arm, 87% of the P-BL patients and 95% of the L patients had AEs. Hospitalizations related to AEs were 13% and 17% for P-BL and L patients, respectively. There were no differences in discontinuation and duration of atezolizumab treatment or time from surgery to adjuvant chemotherapy/atezolizumab. In P-BL patients, adjuvant atezolizumab had no new safety signals and was well tolerated.

###

Presented by Jay Lee, MD, May 17, 2022, at the AATS 102nd Annual Meeting

ABOUT THE AMERICAN ASSOCIATION FOR THORACIC SURGERY (AATS)

The American Association for Thoracic Surgery (AATS) is an international organization that encourages, promotes, and stimulates the scientific investigation of cardiothoracic surgery. Founded in 1917 by a respected group of the earliest pioneers in the field, its original mission was to “foster the evolution of an interest in surgery of the Thorax.” Today, the AATS is the premiere association for cardiothoracic surgeons in the world and works to continually enhance the ability of cardiothoracic surgeons to provide the highest quality of patient care. Its more than 1,500 members have a proven record of distinction within the specialty and have made significant contributions to the care and treatment of cardiothoracic disease. Visit www.aats.org to learn more.